Enzymatically-produced dimeric IL-2 and a nerve-derived transglutaminase enzyme for its preparation
US5514565A · kind A · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 1993 |
| Grant date | May 7, 1996 |
| Priority date | — |
| Expiry date | Jul 30, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a new nerve-derived transglutaminase enzyme that converts immune-derived IL-2 to dimeric IL-2 having oligodendrocyte cytotoxic activity. Both the nerve-derived transglutaminase and the dimeric mammalian, e.g. human, IL-2, are for use as active ingredients in pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.